Clinical Trials Browser

Brentuximab Vedotin × Dermatologic × 1 year × Clear all

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

161 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase 2 Active not recruiting

79 enrolled

DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT07178457 2025-09-17

BeCALM

Phase 3 Not yet recruiting

84 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

26 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Clinical Trials

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

BeCALM

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma